This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Teva In-Focus: A New Webinar Series For The Investment Community Focusing On Teva’s R&D Activities

In an effort to keep our shareholders and analysts informed and up to date on the progress of our promising R&D programs, we are launching Teva In-Focus .

This new webinar series provides an in-depth view of Teva’s R&D strategies and progress in primary therapeutic areas in a format that is focused, detailed, and accessible.

Teva In-Focus kicks off on Tuesday, October 8 th at 8:00am Eastern Time with a focus on our Respiratory franchise, providing insight into Teva’s commercial and R&D franchise as well as our strategy for building a leadership position in respiratory therapies.

Teva In-Focus will include a review of the global market and unmet needs, our approach to innovation and therapeutic development, and a deep dive into key projects that we believe will drive Teva’s future growth in the respiratory market.

Dr. Michael Hayden, Teva’s President of Global R&D and Chief Scientific Officer, will lead the webinar and will be joined by Teva’s respiratory franchise leadership including Hans Luijendijk, Head of Global Respiratory Marketing, Global Specialty Medicine Group and Dr. Tushar Shah, Global Respiratory R&D, Teva Global R&D.

A question and answer session will follow the presentation.

Webinar access details:


Meeting Title:

  Teva Respiratory Webinar

Meeting Date:

October 08, 2013

Meeting Time:

08:00 AM [Eastern Time]


1 Hour 30 Minutes

Webcast Link:


Dial-in details:


1 (800) 303-0442

US Toll Free

1 (847) 413-3733


Confirmation Number:


About Teva

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's leading generic drug maker, with a global product portfolio of more than 1,000 molecules and a direct presence in about 60 countries. Teva's branded businesses focus on CNS, oncology, pain, respiratory and women's health therapeutic areas as well as biologics. Teva currently employs approximately 46,000 people around the world and reached $20.3 billion in net revenues in 2012.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs